Therapeuticsmd (TXMD) revenue and earnings history
Therapeuticsmd reported revenue of $3.02M for fiscal 2025 (year ended Dec 31, 2025), +71.6% on the year before, and net income of −$569K.
Over 14 years, from fiscal 2011 to fiscal 2025, revenue grew at a compound rate of +2.7% a year.
Revenue and net income, 16 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $3.02M+71.6% | −$4.39M | −$569K | $2.45M | — | — | $75K | — | — | $7.48M | — | 10-K/A |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Therapeuticsmd (TXMD) on OQRO.
Common questions
What was Therapeuticsmd's revenue in fiscal 2025?
$3.02M for the year ended Dec 31, 2025, as reported in its 10-K/A filed Apr 1, 2026. That is +71.6% on fiscal 2024 ($1.76M).
How fast has Therapeuticsmd's revenue grown?
From $2.09M in fiscal 2011 to $3.02M in fiscal 2025: a compound annual growth rate of +2.7% over 14 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Therapeuticsmd been profitable?
It reported a net loss in 15 of the years shown (2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2023, 2024, 2025). The highest net income was $112M in fiscal 2022.
Where these figures come from
The SEC’s companyfacts data: every figure Therapeuticsmd tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
